Fenfluramine Hydrochloride Drug Due Diligence Report 2026

This Fenfluramine Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Fenfluramine Hydrochloride can convert its Small molecule drug profile and 5-HT1D receptor x 5-HT2A receptor x 5-HT2C receptor x SERT x σ1 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fenfluramine Hydrochloride (query alias: fenfluramine)
Modality / target	Small molecule drug; 5-HT1D receptor x 5-HT2A receptor x 5-HT2C receptor x SERT x σ1 receptor; 5-HT1D receptor agonists, 5-HT2A receptor agonists, 5-HT2C receptor agonists
Highest global status	Approved
Originator	Zogenix, Inc.
Active developers	Zogenix, Inc., UCB Pharma SA, Zogenix International Ltd.

The MCP disease footprint includes Lennox Gastaut Syndrome, Epilepsies, Myoclonic, Seizures. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07112365	Phase 4	Recruiting	25	Change in blood oxygenation level in response to CO₂
NCT07503444	Phase 3	Not yet recruiting	200	Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score
NCT07651293	Not Applicable	Not yet recruiting	46	Change in cortical [11C]Cimbi-36 non-displaceable binding potential (BPND) after dl-fenfluramine versus placebo (serotonin release capacity)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 1, Single-Center, Repeat-Dose, Open-Label, Fixed-Sequence Drug-Drug Interaction Study of ZX008 in Healthy Male Or Female Study Participants 18 To 55 Years Of Age

Phase 1; n=22; evaluation: not stated. Reported fields: Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State(Geometric Mean) = 8.203 nanograms per milliliter (ng/mL) (Geometric Coefficient of Variation, 40.6); Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State(Geometric Mean): Geometric Least Square Mean (GLSM) Ratio = 0.7854(90% CI, 0.6893 - 0.8949); Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State(Geometric Mean): Geometric Least Square Mean (GLSM) Ratio = 0.7854(90% CI, 0.6893 - 0.8949)

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome

Phase 3; n=412; evaluation: not stated. Reported fields: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) = 75.5 percentage of participants ; -; -

Safety, Tolerability, Pharmacokinetics, and Efficacy of Fenfluramine in Combination With Cannabidiol: Results From a Phase 1 Study (P9-9.010)

Phase 1; n=9; evaluation: Positive. Reported fields: Highest concentrations = 81.3 ng/mL ( 2 - hours post - dose); Highest concentrations = 72.6 ng/mL ( 4 - hours post - dose)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fenfluramine Hydrochloride addresses Lennox Gastaut Syndrome, Epilepsies, Myoclonic, Seizures. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-02-23	Nippon Shinyaku : Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL	Approved	Financial terms not disclosed
2022-01-19	UCB SA acquires Zogenix, Inc.	Approved	US$1,441.2M stated total
2019-03-19	Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan	NDA/BLA	US$148.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Processes for the Preparation of Fenfluramine”. The milestone feed surfaced a patent-application signal described as “Fenfluramine for treatment of conditions associated with spreading depolarization”. The milestone feed surfaced a patent-application signal described as “Fenfluramine for treatment of demyelinating diseases and conditions”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO